Cambridge, UK, 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.
Eliot brings more than 25 years of extensive leadership experience in clinical-stage biopharmaceutical companies. Most recently, he served as CEO of Immunocore where he successfully steered the company’s strategy in immuno-oncology (IO), raising a $320M Series A and establishing…
Royalty bearing license agreement to commercialise a product incorporating the Affimer technology
Wetherby and Cambridge, UK, 10 October 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.
Avacta and NEB have been collaborating to…
Cambridge, UK, Oct 10 2018: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Dr. Yost, Professor and Head of Analytical Chemistry at the University of Florida, is an internationally recognized leader in the field of analytical chemistry. He has particular expertise in tandem mass spectrometry and is the co-inventor of the triple quadrupole mass spectrometer, which today represents over $1 billion…
Life science businesses can learn all about new plans to improve personalised healthcare, at an Interreg North-West Europe event, hosted by the University of Leicester and supported by Medilink Midlands.
The free CoDex4SMEs roadshow will take place on Thursday, October 11, from 09:30am until 14:30pm at Stamford Court at the University of Leicester on Manor Road (LE2 2LH). CoDex4SMEs is designed to help life-science businesses improve their use of companion diagnostics. It is a three-year programme which will run across seven countries, with nine project partners and two sub-partners.…
Acquired donor center and laboratory enables BioIVT to ship high quality blood products and blood-derived immune cells efficiently to researchers throughout Europe
Westbury, NY – Oct. 8, 2018 – BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
“We are delighted that CTLS is now part of…
Glasgow, UK based - ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service.Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.At the recent Miptec conference in Basle, Switzerland - ScreenIn3D was one of 60 global organisations invited to showcase its cutting-edge life science technologies for research, science…
Oxford, UK, 08 October 2018: Aigenpulse Ltd., (Aigenpulse), a company at the forefront of employing data technologies and advanced machine learning to accelerate drug discovery, today announced the appointment of Dr Satnam Surae as Chief Product Officer. The appointment continues the rapid expansion of the company, which has grown four-fold in the last year and is the first in a series of senior appointments.
Dr Surae was the first employee at Aigenpulse when he joined in October 2016, and most recently held the role of Lead Computational Biologist. He has extensive experience in…
Research Triangle Park, NC and Cambridge, UK, September 24, 2018 -- Inivata, a leader in liquid biopsy today announces that results from its US multi-centre prospective validation study of its InVisionFirst-Lung liquid biopsy test will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).The data will be presented by the lead author of the study, Dr Ramaswamy Govindan, Professor of Medicine, at the Washington University School of Medicine, on September 25, 13.30-15.00: Prospective clinical validation of the…
21 September 2018
Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US. The site which opened for business in Massachusetts on Friday 21st September will help support Axol’s customer base in the United States and Canada.
Commenting on the move, Rob Treanor, Axol’s Head of Supply said: “Our new facility allows us to greatly enhance the service level and support we provide for our US customers. By investing in a local presence in the US, we take a step closer to achieving our aspiration of being the leading…
20 September 2018
Cambridge, UK, 20th September 2018 / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly during his tenure, delivering numerous development candidates across several therapeutic areas. Following his education at the University of Cambridge, Dr Perrior undertook academic research at…